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Background: The 360° fusion of lumbar segments is a common and well-researched therapy to treat various
diseases of the spine. But it changes the biomechanics of the spine and may cause adjacent segment disease
(ASD). Among the many techniques developed to avoid this complication, one appears promising. It combines a
rigid fusion with a flexible pedicle screw system (hybrid instrumentation, “topping off”). However, its clinical
significance is still uncertain due to the lack of conclusive data.
Methods/Design: The study is a randomized, therapy-controlled, two-centre trial conducted in a clinical setting at
two university hospitals. If they meet the criteria, outpatients presenting with degenerative disc disease, facet joint
arthrosis or spondylolisthesis will be included in the study and randomized into two groups: a control group
undergoing conventional fusion surgery (PLIF - posterior lumbar intervertebral fusion), and an intervention group
undergoing fusion surgery using a new flexible pedicle screw system (PLIF + “topping off”), which was brought on
the market in 2013.
Follow-up examination will take place immediately after surgery, after 6 weeks and after 6, 12, 24 and 36 months.
An ongoing assessment will be performed every year.
Outcome measurements will include quality of life and pain assessments using validated questionnaires (ODI -
Ostwestry Disability Index, SF-36™ - Short Form Health Survey 36, COMI - Core Outcome Measure Index). In addition,
clinical and radiologic ASD, sagittal balance parameters and duration of work disability will be assessed. Inpatient
and 6-month mortality, surgery-related data (e.g., intraoperative complications, blood loss, length of incision, surgical
duration), postoperative complications (e.g. implant failure), adverse events, and serious adverse events will be
monitored and documented throughout the study.
Discussion: New hybrid “topping off” systems might improve the outcome of lumbar spine fusion. But to date,
there is a serious lack of and a great need of convincing data on safety or efficacy, including benefits and harms to
the patients, of these systems. Health care providers are particularly interested in such data as these implants are
much more expensive than conventional implants. In such a case, randomized clinical trials are the best way to
evaluate benefits and risks.
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Lumbar spine fusion is a controversial surgery. While
some evidence suggests that it could be more efficient
than commonly used nonsurgical treatment, there is also
evidence to the contrary [1]. But in spite of the inconclu-
sive results, it remains a well-established and frequently
used surgical treatment for various diseases of the lum-
bar spine and chronic low back pain.
Spinal fusion is known to change the biomechanics of
the spine, e.g. it can result in increased motion in the seg-
ments adjacent to the fused level. Outweighing the initial
clinical benefits from the surgery, this motion may cause
adjacent segment disease (ASD) that is defined as the clin-
ical presence of symptoms which correlates to degenerative
disease adjacent to the index level with the radiographic
presence of disease. It must be distinguished from adjacent
segment degeneration, a radiological term that does not
lead to clinical symptoms [2].
Thus different techniques (disc arthroplasty and dy-
namic stabilization) have been developed to prevent this
degeneration [3]. In this context, the posterior dynamic
stabilization (PDS) is one of the most rapidly evolving
technique, including various types of flexible pedicle
screw systems, such as the “topping off” version men-
tioned above. Other PDS devices include interspinous
spacers used by some surgeons together with a mono-
segmental rigid fusion [4]. To simplify the discussion of
these devices, Khoueir et al. [5] classified them into:
1. Interspinous spacer devices;
2. Pedicle screw/rod-based devices; and
3. Total facet replacement systems.
The concept behind these devices is to maintain or re-
store intervertebral motion in a controlled manner, whether
by preventing excessive spinal movement or by dampening
the kinetic energy. They are designed to mimic the behav-
iour of the healthy spinal column [5,6]. Various types of
flexible pedicle screw systems (e.g. Dynesis™, DSS™, cosmic-
MIA™) and “topping off” systems (e.g. DTO™, BalanC™,)
have been developed.
The ”topping off” technique has been reported to pro-
vide dynamic stabilization and to reduce degeneration in
the adjacent segment [7,8]. Some studies report better
clinical outcomes in patients with partial fusion than
with solid fusion, they suggest that reducing, rather than
eliminating, segmental motion alleviates pain. It could
be a promising alternative to multilevel fusion [9] and,
according to Coe et al., to rigid fusion [10].
One of the most extensively used posterior dynamic
stabilization systems is Dynesys®, in which pedicle screws
are connected across spinal motion segments with non-
elastic bands to provide controlled motion. In early clin-
ical outcomes, it has been shown to lessen pain anddisability in patients with degenerative spondylolisthesis and
central or lateral spinal canal stenosis. Comparable clinical
outcomes of other pedicle-based dynamic stabilization sys-
tems have also been reported [11,12]. However, in a pro-
spective, randomized clinical trial of 60 patients comparing
hybrid with conventional fusion over 6 years of follow-up,
clinical results did not differ between the groups (ODI,
VAS, satisfaction). Hybrid fixation caused less degeneration
in the adjacent segment, but showed a higher rate of im-
plant failure. This study group did not recommend prophy-
lactic dynamic stabilization [13].
In patients with lumbar spinal stenosis that underwent
decompression and stabilization with the Accuflex™ dy-
namic system, Reyes-Sánchez et al. report a relatively
high hardware failure (22%), but also clinical benefits
and cessation of the degenerative process in 83% of the
patients [11].
As a summary, it can be said that there is still no evi-
dence of any clinical benefit from these systems.
Another issue is whether the radiographically detectable
adjacent degeneration is an indicator of clinical outcome.
As already mentioned, spinal fusion creates increased
strain on adjacent levels and can result in ASD. Adjacent
instability has been reported even 6 to 12 months after
surgery [3,14], with varying average rates. In a retrospect-
ive study, Cheh et al. identified radiographic ASD in 42.6%
of the patients (average follow-up of 7.8 years). Oswestry
scores were worse in patients with radiographic ASD.
Clinical ASD developed in 43% [3]. Other authors re-
ported an incidence of ASD of up to 24% (average follow-
up of 39 months). In that study, instability developed more
frequently above the fusion [14]. Yang et al. found a sig-
nificant correlation between clinical outcome and ASD
[15]. In a 30-year follow-up comparing patients undergo-
ing various spinal procedures (fusion, discectomy, decom-
pression), Kumar et al. [16] found that the incidence of
radiographic changes in levels above the operated region
was twice higher after fusion than after the other proce-
dures. In contrast, validated scales and functional testing
(e.g. SF-36) showed no significant differences in outcome.
The authors concluded that radiographic changes do not
necessarily lead to functional impairment in all patients.
Other evidence suggests that radiologic degeneration of
the superior adjacent segment does not correlate with
clinical results [17]. Ghiselli et al. reported an adjacent
segment disease rate of 16.5% after 5 years in a collective
of 215 patients who had undergone lumbar spine arthrod-
esis. This rate went up to 30.1% at ten years follow-up
[18]. However, a previous review mentions a correlation
between fusion and adjacent segment degeneration com-
pared to arthroplasty. This correlation appears to be even
stronger if adjacent segment disease is observed, thus
underlining the impact of fusion on the adjacent segments
[2]. In this context, sagittal imbalance is another factor of
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vours the development of the disease [19,20].
Objective
The objective of the study is to address the following
questions:
Does posterior hybrid stabilization with a new topping
off device lead to a better or at least equivalent clinical
outcome compared to standard fusion? Clinical outcome
assessment will be performed using ODI, SF-36 and
COMI questionnaires.
Does it prevent adjacent instability/segment disease?
Does radiographic ASD correlate with clinical outcome?
Does this new device lead to a higher complication rate
(e.g. implant failure) than standard fusion?
Methods and design
The study is a randomized, parallel-group, therapy-
controlled trial in a clinical setting at two university hospi-
tals. Outpatients presenting with degenerative disc disease,
symptomatic facet joint arthrosis or spondylolisthesis will
be assessed for inclusion. They will be asked to give an in-
formed consent and will be randomized before surgery.
Follow-up examinations will take place immediately after
surgery, and after 6 weeks, 3 months and 6 months, the
total duration of the study. Furthermore data will be
assessed after 12, 24 and 36 months for a supplemental in-
vestigation. A further assessment will be performed every
year, as it may be impossible to pronounce on ASD after
36 months.
This trial has received the approval of the ethics com-
mittee of the medical faculty of the University of Co-
logne under the reference number 12–231. The Clinical
Trial Centre of the University of Cologne will monitor
and manage the data. The research will be carried out in
compliance with the Helsinki Declaration [21].
Participants and recruitment
Outpatients over 30 years of age presenting with degen-
erative disc disease, facet joint arthrosis or spondylolisth-
esis, and indications for monosegmental lumbar spine
fusion will be eligible for trial inclusion. Radiologic in-
clusion criteria are summarized in the Appendix.
The presence of radiologic degeneration of the adja-
cent segment (Pfirrmann grades II-IV in MRI findings
[22]) without signs of instability will be a condition for
inclusion. The definition of radiologic and clinical in-
stability and the other inclusion criteria are summarized
in the Appendix.
Experienced spine surgeons will approach and recruit
the study subjects. The number of patients who undergo
primary monosegmental fusion in the departments is es-
timated at 200 per year and the number of recruited pa-
tients at 20 per year per centre.Patients participating in parallel interventional studies
as well as patients with lumbar scoliosis (>25° cobb
angle), spondylolisthesis Meyerding IV, adjacent segment
instability and/or radiologic ASD worse than Fujiwara
grade II or Pfirrmann grade IV [22,23] will be excluded
from this study. This also applies to patients with indica-
tion for multilevel fusion. The other exclusion criteria
are summarized in the Appendix.
Interventions
Patients will receive one of two treatments:
▪ Monosegmental posterior lumbar intervertebral
fusion (PLIF)
▪ Hybrid system (PLIF + flexible pedicle screw system
above the fusion)
Control group - conventional PLIF
The control group will be treated with a conventional,
monosegmental posterior lumbar spine fusion with a
rigid pedicle-based instrumentation and posterior inter-
vertebral cages (PLIF), the current well-established ther-
apy for several pathologies of the lumbar spine (see
Appendix under “Inclusion Criteria”). Thus, the control
group will receive the standard of care. This is the only
acceptable control/comparison in a trial of this kind.
Surgery will be performed using the following devices:
S4® AESCULAP AG, Cage: Wave® Cage (Fa. Medtronic®).
Intervention group - hybrid system
The intervention group will be treated with a hybrid sys-
tem with PLIF (rigid pedicle-based instrumentation and
posterior intervertebral cages) and a flexible pedicle screw
system above the fusion. Surgery will be performed using
the following devices: S4® Dynamic rod (AESCULAP AG,
Tuttlingen), Wave® Cage, (Fa. Medtronic ®). The dynamic
connecting rod of the S4 Spinal System is used for the dy-
namic monosegmental stabilization through the dorsal ap-
proach and the fusion of one or two adjacent segments. It
consists of a spring element, a short rod section on one
side, and another rod section that varies in length on the
other side. The materials used in the implant are pure ti-
tanium and titanium forged alloy Ti6Al4V. The prototype
of this dynamic implant has already been biomechanically
tested and compared with other dynamic devices and a
rigid one; no significant ROM reduction (extension,
flexion, lateral bending) was detected. In addition, the
implant brought about a significant reduction of axial
rotation [24].
Surgery and treatment
Only skilled spine surgeons (experience of at least 30
fusions-procedures/per year) will participate in the trial.
To avoid variations in surgical procedure (e.g. size of
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instructional video on the standards of the procedure
will be provided to the surgeons. In both groups, autolo-
gous bone spongiosa, harvested during the decompres-
sion procedure, will be implanted in the intervertebral
disc space with the intervertebral cages.
The patients will have the surgical drain removed
2 days after surgery. Beginning on the day after surgery,
both groups will receive physical therapy. Patients will
be discharged only after appropriate recovery if wound
healing is progressing normally. They will remain in the
hospital for 8–10 days. After hospital discharge, they will
continue to receive physical therapy as outpatients, but
not in standardized form to reproduce real conditions.
Outcome measures and assessments
Primary outcome measures
This investigation focusses on the subjective and objective
clinical benefits for the patient. The ODI scores will be
used to evaluate the functional outcomes after 6 weeks
and after 6, 12, 24 and 36 months after surgery. The study
hypothesis is:
The improvement in ODI scores from baseline to
6 months after surgery is clinically superior in the group
with D-Rod (μRod) compared with the group without
D-rod (μ).
To prove it, the following null hypothesis must be
rejected: H0: |μRod - μ| ≤MCID;
The alternative hypothesis is: H1: |μRod - μ| >MCID,
with MCID assigning for minimum clinically important
difference.
The hypothesis will be tested using a two-sided t-test
for independent samples with a significance level of 5%.
In accordance with the recommendations of the
European Agency for the Evaluation of Medicinal Prod-
ucts (EMEA), the patient’s bodily function may not be im-
paired if the only medical benefit is to relieve pain [25].
The ODI (cross-cultural adaption of the ODI version 2.1
for use with German-speaking patients) is a standardized,
condition-specific questionnaire that gives a subjective
percentage score of level of function (disability) in 10
everyday activities of daily living to be completed by pa-
tients rehabilitating from low back pain [25].
In the past, spine surgery investigations have focused on
technical outcomes; now the main interest has turned to
clinical outcomes [26,27], measured by the ODI and SF-
36™ , as in recent important trials (RCTs) [28,29]. Radio-
logic findings are poor indicators of clinical outcome as it
is unclear whether they correlate with clinical success.
Secondary outcome measures
1. PCS of the SF-36™. The SF-36™ is the most
frequently used generic health status measureworldwide that includes parameters such as pain
and walking distance. It has been further developed
to comprise physical (PCS) and mental health
(MCS) component scores, thus easing the
interpretation and cross-cultural comparison. It is a
standardized questionnaire used to evaluate the
patients’ health-related quality of life. It yields an
8-scale profile of functional health and well-being
scores, as well as psychometrically based physical
and mental health summary measures, and a
preference-based health utility index. Thus, the
SF-36™ is a good measure of primary endpoint. The
patients' answers are scored and added together to
yield a sum total. The SF-36™ PCS scores of the
experimental and control groups will be compared to
further quantify patient outcomes. In the subsequent
follow-ups, the SF-36™ will be repeated to detect any
clinical impairment and/or clinical or radiologic
instability. This follow-up will continue for up to 3 years
and then each year after surgery. In cases of impairment,
X-ray is indicated at any point of time. In total, MCS
and 8 individual dimensions and subscales of the
SF-36™ (version 4.0) are used to confirm and clarify
the primary outcome results.
2. COMI questionnaire (2008 version) - a short, patient-
oriented, multidimensional outcome instrument
validated for patients with spinal disorders.
3. X-rays will be taken after 6 weeks, and after 6, 12,
24, and 36 months. A further assessment will be
performed every year. These are common intervals
after surgical implantation without extraneous
radiation. If adjacent instability is discovered on a
X-ray, the clinical outcome will be reevaluated. The
criteria for both radiologic ASD and adjacent
instability are listed in the Appendix (definition of
radiologic instability and Weiner’s classification).
Experienced radiologists will evaluate the pre- and
postoperative X-rays to calculate the score in Weiner’s
classification. Furthermore, after 6 months, full-length
X-rays of the spine will be taken to assess sagittal balance
parameters (pelvic incidence, sacral slope, pelvic tilt,
lumbar lordosis, C7 plum line, SVA). At each follow-
up visit, bone fusion will be evaluated by indirect signs
(screw loosening, implant failure, loss of reduction).
4. Clinical ASD will be assessed (see definition in the
Appendix).
5. Work disability at the time of and after surgery, and
duration until return to work. At each visit, patients
will be asked to grade their disability, and whether
or when they have returned to work.
6. Inpatient mortality and mortality at 6 months.
7. Surgery-related data (blood loss, length of incision,
duration of surgery) will be taken from the surgical
report.
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administered to the patients will be documented. If the
patient complaints of pain, the medication will be
adjusted. The adjustment will be recorded on the CRF.
9. Intraoperative and postoperative complication rate
(e.g. implant failure- see Appendix under “Safety”)
10. Adverse Events (AE) and Serious Sdverse Svents
(SAE) will be monitored and documented
throughout the study (see Appendix under “Safety”
and “AE and SAE”).
Sample size
On the basis of the data provided by Parker et al., the
standard deviation is set at 11.3 points and the minimal
clinically relevant difference at 11 for the changes in the
Oswestry Disability Index (ODI) scores between the
baseline and six months. In order to detect this clinically
relevant difference between the two treatment groups,
using a two-sided t-test with a significance level of 5%
and a power of 80%, a total of 36 patients is required (18
per group) [30].
Assuming a drop-out rate of 10% until follow-up, 40
patients must be recruited for the study.
At a recruitment rate of 50% of the eligible patients
and a rate of 60% of eligible patients in the screened
population, 80 patients must be eligible among the 133
screened patients.
At a screening rate of approx. 100 patients in 12 months,
duration of recruitment would be 16 months. To comply
with the CONSORT requirements, we will provide a flow
diagram of the participants. For each group, it will show
the numbers of participants who were randomly assigned,
received intended treatment, and were analysed for the
primary outcome. Furthermore a diagram will illustrate
for each group, losses and exclusions after randomization,
together with reasons [31].
Randomization
The patients will be assigned to the two treatment groups
using an electronic randomization system provided by
Aesculap®.
Balanced centre-stratified randomization with blocks
of variable length. The randomization algorithm is im-
plemented using statistical package SAS 9.2 and modi-
fied according to Dmitrienko et al. [32].
Data management
At the study sites, the data will be entered online in a
validated study database (eCRF) by trained personal.
During data entry, plausibility tests will be carried out to
tackle inconsistencies immediately. Later, a data manager
will repeatedly check the data for completeness and
plausibility and resolve the inconsistencies in concertwith the centre. The central IT infrastructure will be
provided by the ZKS.
The study database will be running on validated study
software (MACRO). The study database itself will be
validated before the data are entered. It will store all
changes made to the data in an audit trail with a user
and role concept adaptable to the specific study. The
database will be integrated in a general IT infrastructure
and security architecture with firewall and backup sys-
tem. The data will be backed up daily.
Data analysis
Primary target variable
The primary target variable is the functional change in the
lumbar spine between baseline and 6 months as measured
by the Oswestry Disability Index (ODI). The two-sided t-
test for independent samples will be used as confirmatory
test to compare the intervention group with the control
group.
Analysis will be based on the intention-to-treat (ITT)
principle. Consistency of the results will be verified by
additional per-protocol (PP) subgroup analysis.
In addition, the results will be evaluated, focusing sep-
arately on each of the three diseases: degenerative disc
disease, degenerative spondylolisthesis und spondylo-
listhesis. This applies to both the results from the ODI
and to all other secondary target variables.
Secondary target variables
All secondary target variables, such as frequency, average
and standard deviation will be tabulated per point of time
(baseline, 6 weeks, 6 months) and per treatment arm. The
historical data for ODI, MCS of SF-36 of PCS of SF-36 will
be expressed as AUCs (areas under the curve) adjusted for
the observation period. Once the data have been collected
after 6 weeks, 6 months and 36 months, the missing
values, if any, will be interpolated after 12 or 24 months,
or the AUC will not be evaluated. The two-sided t-test for
independent samples will be used to compare the inter-
vention group with the control group. The Logrank test
will be used to compare the treatment groups in terms of
survival time to instability measured by the Kaplan-Meier
method. The link between time to instability and the
ODI will be investigated by correlation analysis. Follow-
ing evaluation of the primary endpoint, the ITT population
and the PP population – as sensibility analysis – will be
analysed.
Monitoring
To ensure proper conduct of the study and reliability of
the results, clinical monitors will visit the trial centres.
For one patient at each trial centre, 100% source data
verification will be carried out.
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the questionnaires will be partially checked against the
case report form data. For each patient, the presence of
a written consent will be verified.
Biases
To avoid potential biases, this study is planned as ran-
domized trial. Blinding will not be attempted because it
cannot be successfully implemented as X-rays must be
taken. Since the hybrid implant is expected to bring ben-
efits in comparison with the conventional one, it must
be tested in comparison to this control group.
To avoid bias without blinding design, the following
measures are planned:
1. Different trial physicians will carry out the surgery
and the questionnaire survey
2. Different trial physicians will carry out the
questionnaire survey and the evaluation of the X-rays
3. The patient will be instructed not to give any details
of his treatment to the trial physician
4. The trial physicians will be trained to evaluate the
X-rays
5. Intraoperative photos will be provided to compare
the surgical techniques (approach, size of
decompression) and, if need be, a video of the
surgery for standardisation and training purposes
Adverse and serious adverse events
Adverse event
An Adverse Event is any untoward medical occurrence
in a study patient that may or may not have a causal re-
lationship with the study treatment. Abnormal labora-
tory test values will be recorded as AE only if they
require treatment.
Concomitant diseases In this context, deterioration of
a pre-existing disease is also to be regarded as an Ad-
verse Event. But it will not be regarded as an Adverse
Event if it is due to a treatment that was already planned
before the patient was enrolled in the study.
Pregnancy In this study, the occurrence of pregnancy is
considered as an Adverse Event. Before surgery, labora-
tory tests will be conducted to exclude pregnancy in
women below 50 years of age.
Laboratory test values Any abnormal laboratory test
values during the study will be checked for plausibility
and evaluated for clinical relevance by the responsible
investigator. If during the study, an abnormal test value
is found that, in the baseline visit, was not considered to
be clinically relevant, but is now considered to be clinic-
ally relevant, it must be recorded as an AE in the eCRF.Serious adverse event
The present clinical study is not subject to the Sections
20-23a of the German Medical Product Law (Medizin-
produktgesetz – MPG), but its definitions will apply
here. A Serious Adverse Event is any untoward occur-
rence in a clinical trial or in a performance evaluation
text subject to approval that
 directly or indirectly leads to death; or
 have led, could have led, or could lead to a serious
deterioration in the state of health of a study
subject, of a user or of another person, irrespective
of whether the occurrence has been caused by the
medical product.
This definition of a SAE will serve as basis for the
documentation of Serious Adverse Events during the
study.
Ascertainment of AE and SAE
The study centre concerned is responsible for recording
and reporting AEs and SAEs. The study director/main
investigator will ensure that all persons involved in the
treatment of the study patients are fully aware of their
responsibilities in the event of Adverse Events. At each
visit, the patients will be asked if they have experienced
any Adverse/Serious Events. The Adverse Events will be
recorded both in the patients’ medical record and in the
survey questionnaires. At each visit, the physician will re-
view the patients’ medical records to determine whether
Adverse Events have occurred.
If an Adverse Event occurs, the patient in question, irre-
spective of the causal relationship between the Adverse
Event and the study treatment, must be kept under con-
stant supervision. In any case, the patient must remain
under observation until the symptoms have subsided, or
the laboratory test values have returned to acceptable
levels, or a plausible explanation has been found for the
Adverse Event, or until the patient has died, or has been
discharged from the study (last visit after 6 months or
36 months).
All Adverse Events will be recorded in the CFR, in-
cluding the following information:
 Time and date of start and end ,
 Gravity ,
 Relationship to the study therapy
 Serious or not serious ,
 Expected or not expected ,
Discussion
New “topping off” hybrid systems might reduce the
complications associated with lumbar spine fusion. But
to date, there is no convincing evidence to confirm this
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viding highly reliable data and a preliminary evaluation
of the advantages and disadvantages of a device that was
launched in 2013. These systems are much more expen-
sive than conventional implants, they should not be im-
planted if they do not bring any appreciable benefit, an
aspect which is of interest to the health care providers.
This study is designed as a randomized clinical trial, a
format highly recommended to evaluate the benefits and
risks to patients of new devices.
In the intervention group, the approach to the spine
will be larger than in the fusion group. This in itself
could bring about a negative outcome compared to that
of standard fusion (e.g., due to muscle damage, blood
loss, higher risk of infection). But implant failure rates
can still be compared between the groups. The crucial
question, however, is the ability to prevent ASD.
To use a placebo in the control group would be funda-
mentally unethical. Not only would it deprive the patient
of adequate treatment, but would also require an inva-
sive procedure without implantation, thus exposing him/
her to significant risks without benefit. Furthermore,





 Age ≥ 30 years
 Indication for monosegmental lumbar spine fusion
L2-S1 with osteochondrosis Modic grades I-III
 Indication for monosegmental lumbar spine fusion
L2-S1 with spondylolisthesis Meyerding grades I-III
(signs of instability in the functional x-rays and a.p.
and lateral view; see definition of radiologic instability).
 Indication for monosegmental lumbar spine fusion
L2-S1 with symptomatic facet joint arthrosis or
degenerative disc disease (>Fujiwara grade II [23]
or > Pfirrmann grade IV [22])
 Radiologic signs of degeneration in the adjacent
segment of the intended fusion without signs of
instability
 Definition of adjacent segment degeneration (MRI)
Pfirrmann [22] grades II-IV
Grade I: Homogeneous bright white structure
Grade II: Inhomogeneous white structure,
possible horizontal bands
Grade III: Clear distinction between annulus and
nucleus
Grade IV: Non-collapsed disk space
Grade V: Collapsed disk space
 Definition of radiologic instability (x-ray: a.p. and
lateral view, extension and flexion):1. Spondylolisthesis >4 mm (anterior or posterior
translation) [3]
2. Segmental kyphosis >10° [3]
3. Rotatory hypermobility >15° [14]
4. Complete collapse of the disc [3]
5. Lateral translation >3 mm [14]
6. Disc wedging >5° [14]
7. Deterioration in Weiner’s classification of 2 or
more grades in the follow-up evaluation [1,27]Weiner’s classification
0 = No disease, defined by normal disc height, no spur
formation, no eburnation, and no gas
1 =Mild disease, defined by <25% disc space narrowing,
small spur formation, minimal eburnation, and no gas
2 = Moderate disease, defined by 25%-75% disc space
narrowing, moderate spur formation, moderate
eburnation, and no gas
3 = advanced disease, defined by >75% disc space




 Cauda equina syndrome
 Previous surgical intervention of the lumbar spine
 Relevant peripheral neuropathy
 Acute denervation subsequent to radiculopathy
 Scoliosis with Cobb angle greater than 25°
 Spondylolisthesis >Meyerding grade III Radiologic signs of degeneration in the adjacent
segment of the intended fusion with signs of
instability (for definition, see inclusion criteria)
 No radiologic signs of degeneration in the adjacent
segment of the intended fusion (for definition, see
inclusion criteria)
 Radiologic signs of degeneration in the adjacent
segment of the intended fusion with > Fujiwara
grade II [23] or > Pfirrmann grade IV [22]
 Signs of instability in any lumbar spine segment
other than that undergoing fusion (patients with
indication for multilevel fusion are excluded)
 General contraindication for elective lumbar spine
surgery
 Pathologic fracture
 Osteoporosis with pathologic fracture
 Active systemic infection
 Rheumatic disease
 Disease of bone metabolism (e.g. Paget’s Disease)
 Bone metastasis
 Local infection of lumbar spine
 Seizure disorder
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classification IIb-IV
 Severe heart insufficiency (NYHA III-IV)
 Blood coagulation disorder or blood thinning
therapy
 Cortisone intake more than one month in the last
12 months before randomization
 Simultaneous participation in another clinical
trial in the 30 days before randomization
 Known allergy or intolerance to the implants
 Dependency on investigator
 Lack of familiarity with the German language
 Placement in an institution by governmental or
juridical order
 Absent legal capacity
 Pregnancy
 Lactation periodDefinition of clinical ASD [14]
1. Symptomatic spinal stenosis
2. Mechanical back pain




3. Rigid rod breakage









 Complications in anaesthesia
 Paralyses, neurologic deficit
 Dura leakage
 Sensibility disorders
 Necessity of a revision
 Thrombosis/pulmonary embolism
 Allergic reaction following administration of
antibiotics
 Risk of HIV, hepatitis B, C etc. after blood
transfusionAbbreviations
a.p.: Anterior-posterior; ASD: Adjacent segment degeneration/disease;
COMI: Core outcome measure index; MCS: Mental health component score;
MRI: Magnetic resonance imaging; NYHA: New York heart association;
ODI: Oswestry disability index; PCS: Physical health component score;
PLIF: Posterior lumbar intervertebral fusion; QALY: Quality-adjusted life years;
RCT: Randomized clinical trial; SF-36™: Short form health survey-36;
VAS: Visual analogue scale.
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